IRIS
TORTORA, GIAMPAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.758
EU - Europa 987
AS - Asia 213
AF - Africa 35
Continente sconosciuto - Info sul continente non disponibili 2
SA - Sud America 2
Totale 2.997
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.703
UA - Ucraina 365
CN - Cina 187
IT - Italia 137
DE - Germania 120
FI - Finlandia 100
NL - Olanda 84
IE - Irlanda 61
SE - Svezia 55
CA - Canada 54
GB - Regno Unito 38
CI - Costa d'Avorio 32
FR - Francia 24
SG - Singapore 10
PK - Pakistan 9
IN - India 5
EU - Europa 2
ZA - Sudafrica 2
CL - Cile 1
EC - Ecuador 1
GR - Grecia 1
HK - Hong Kong 1
ID - Indonesia 1
MX - Messico 1
RU - Federazione Russa 1
SI - Slovenia 1
TN - Tunisia 1
Totale 2.997
Salva come PNG Salva come JPEG
Città #
Jacksonville 364
Chandler 308
Millbury 133
Woodbridge 89
Princeton 85
Amsterdam 82
Ashburn 64
Wilmington 60
Nanjing 54
Ottawa 52
Beijing 47
Boston 36
Ann Arbor 31
Boardman 26
Nanchang 25
Houston 20
Naples 19
Norwalk 16
Shenyang 15
Kronberg 14
Hebei 12
Changsha 9
Islamabad 9
Tianjin 7
Jiaxing 6
Singapore 6
Kunming 5
Walnut 4
Galdo 3
Los Angeles 3
Napoli 3
Pune 3
Rome 3
San Mateo 3
Seattle 3
Washington 3
Aversa 2
Bari 2
Bloemfontein 2
Des Moines 2
Grumo Nevano 2
Indiana 2
La Canada Flintridge 2
Osimo 2
Rapolla 2
Ravenna 2
Redwood City 2
San Giovanni Teatino 2
Andover 1
Augusta 1
Bologna 1
Castelvetrano 1
Changchun 1
Cologne 1
Dublin 1
Falls Church 1
Frattamaggiore 1
Fremont 1
Giugliano In Campania 1
Guangzhou 1
Hicksville 1
Islington 1
Jakarta 1
Lanzhou 1
Lecce 1
Leeds 1
Lviv 1
Mexico City 1
Monte Di Procida 1
Montréal 1
Mountain View 1
New Delhi 1
Omsk 1
Orange 1
Palma Campania 1
Perugia 1
Porto Sant'elpidio 1
Salerno 1
San Diego 1
San Donato Milanese 1
Santa Clara 1
Shanghai 1
Torino 1
Toronto 1
Varedo 1
Zhengzhou 1
Totale 1.684
Salva come PNG Salva come JPEG
Nome #
Manuale di Oncologia Clinica 95
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. 53
Mitoxantrone, etoposide and bleomycin (MEB) chemotherapy in non-Hodgkin's lymphoma patients non-elegible for standard cyclophoshamide, doxorubicin, vincristine and prednisone (CHOP) combination. 49
ANTITUMOR ACTIVITY OF ZD6474, A VEGFR-2 AND EGFR SMALL MOLECULE TYROSINE KINASE INHIBITOR, IN COMBINATION WITH SC-236, A CYCLOOXYGENASE-2 INHIBITOR. 49
A novel mdm2 antisense oligonucleotide has antitumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer. 49
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. 46
8-Chloro-cAMP inhibits smooth muscle cell proliferation in vitro and neointima formation induced by ballon injury in vivo. 46
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. 46
Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling. 46
Paraneoplastic sensitive neuropathy associated with anti-hu antibodies in a neuroendocrine tumor of duodenum: a case report. 46
Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide. 45
Enzastaurin inhibits tumors sensitive and resistant to anti-EGFR drugs 44
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. 43
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. 43
Combination of biological therapies in non-small cell lung cancer. 43
Antitumor activity of combined treatment of human cancer cells with ionizing radiations and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. 43
A novel thyroid transcript negatively regulated by TSH. 43
Cyclic AMP-dependent protein kinase type I is involved in hypersensitivity of human breast cells to topoisomerase II inhibitors. 42
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an EGFR-selective tyrosine kinase inhibitor. 41
Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. 41
Antiangiogenic and antitumor activity of anti-EGFR C225 monoclonal antibody in combination with Vascular Endothelial Growth Factor antisense oligonucleotide in human GEO colon cancer cells. 41
Angiogenesis: A target for cancer therapy. 40
MONOCLONAL ANTIBODIES TARGETING THE EPIDERMAL GROWTH FACTOR RECEPTOR. 40
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. 40
Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments. 39
ANTITUMOR ACTIVITY OF THE COMBINATION OF CETUXIMAB, AN ANTI-EGFR BLOCKING MONOCLONAL ANTIBODY AND ZD6474, AN INHIBITOR OF VEGFR AND EGFR TYROSINE KINASES. 39
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. 39
Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells. 39
Antitumor effects of ZD6474, a small molecule Vascular Endothelial Growth Factor receptor tyrosine kinase inhibitor, with additional activity against Epidermal Growth Factor. 38
EGFR antagonists in cancer treatment. 38
The use of xenograft models for the selection of cancer treatments with the EGFR as an example. 37
Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis and cooperates with cytotoxic drugs in human cancer cell lines. 36
Anti-epidermal growth factor receptor drugs in cancer therapy. 35
Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J Natl Cancer Inst. 1996 Dec 4;88(23):1770-6. 35
Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity. 34
A Novel Toll-Like Receptor 9 Agonist Cooperates with Trastuzumab in Trastuzumab-Resistant Breast Tumors through Multiple Mechanisms of Action 34
INTRINSIC AND ACQUIRED RESISTANCE TO EGFR INHIBITORS IN HUMAN CANCER THERAPY. 34
Overexpression of wild-type p53 ovverrides the mitogenic effect of the RIa subunit of protein kinase A in human breast cells. 33
Novel TLR9 agonist induces EGFR inhibition and synergistic antitumor activity with EGFR inhibitors. 33
Combined targeting of EGFR and VEGF-dependent pathways: rationale, preclinical studies and clinical applications 33
Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting Protein Kinase A in combination with docetaxel and anti-EGFR-Receptor antibody on human breast cancer cell growth. 32
Synergistic inhibition of growth and induction of apoptosis by 8-chloro-cAMP and paclitaxel or cisplatin in human cancer cells. 32
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases 32
Combined targeted inhibition of Bcl-2, Bcl-xL, EGFR and Protein Kinase A Type I causes potent antitumor, apoptotic and antiangiogenic activity 32
Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. 32
Altri tumori gastrointestinali 32
CHEMOSENSITIZATION BY ANTISENSE OLIGONUCLEOTIDES TARGETING MDM2. 31
Key cancer cell signal transduction pathways as therapeutic targets. 31
8-Chloro-cyclic AMP inhibits autocrine and angiogenic growth factor production in human colorectal and breast cancer. 31
The mechanisms of resistance to EGFR inhibitors. 31
Combined blockade of PKA and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis. 30
Oral antisense targeting protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis and growth factors production. 29
TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. 28
Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. 28
Inhibition of growth factors production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. 28
null 27
Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. 27
The rationale for the combination of selective EGFR inhibitors with cytotoxic drugs and radiotherapy. 24
Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. 24
Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A. 24
Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective EGFR-tyrosine kinase inhibitor ZD1839 (‘Iressa’) 24
Phase I clinical trial of high dose recombinant interleukin-2/veparimil combination in advancer cancer. 24
Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. 23
Helicobacter pylori VacA toxin up-regulates Vascular endothelial growth factor expression in MKN 28 gastric cells through an Epidermal growth factor receptor-, Cyclooxygenase-2-dependent mechanism 23
ZD1839 (Iressa): preclinical studies and pharmacology. 23
Effect of thymic extract "thymostimulin" on the incidence of infections and myelotoxicity during adjuvant chemotherapy for breast cancer. 23
Preclinical and phase I study of oxaliplatin and topotecan in combination in human cancer. 22
Synergistic growth inhibition and induction of apoptosis by a novel mixed backbone antisense oligonuclotide targeting CRIPTO in combination with C225 anti-EGFR monoclonal antibody and 8-Cl-cAMP in human GEO colon cancer cells. 21
Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting protein kinase A. 21
Inhibition of bcl-2 as cancer therapy. 21
Cooperative antitumor effect of mixed backbone oligonucleotides targeting protein kinase A in combination with cytotoxic drugs or biologic agents. 21
Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. 21
Expression of epidermal growth factor receptor (EGFR) correlates with disease relapse and progression to androgen-indepedence in human prostate cancer 20
ZD1839 (‘Iressa’), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. 20
In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches. 20
8-Chloro-cAMP enhances the growth inhibitory effect of cytotoxic drugs in human colon cancer cells 20
The RIalpha subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-receptor. Oncogene. 1997 Feb 27;14(8):923-8. 19
LY2109761, a Novel Transforming Growth Factor ß Receptor type I and II dual inhibitor, as a Therapeutic Approach to Suppressing Pancreatic Cancer Metastasis. 19
EGFR-targeting agents in oncology 19
Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-lerm follow-up. 19
Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. 18
Targeting of Epidermal Growth Factor Receptor and Protein Kinase A : Molecular basis and therapeutic applications. 18
Mechanisms of resistance to HER/erbB inhibitors 18
Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumour activity with EGFR inhibitors 18
Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity. 17
Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumors sensitive and resistant to anti-EGFR drugs 17
Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence. 17
VEGF Receptor 1 contributes to resistance to anti-EGFR drugs in human cancer cells. 16
The cAMP-dependent protein kinase type I is involved in hypersensitivity of human breast cells to topoisomerase II inhibitors. 16
Differential immunohistochemical detection of transforming growth factor , amphiregulin and CRIPTO in human normal and malignant breast tissues. 15
Differential sensitivity to non-MHC-restricted rIL-2 activated lymphocyte killing of human mammary epithelial MCF-10A cells overexpressing oncogenes or PKA subunits. 15
Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer. 15
Strategies for multiple signalling inhibition. 14
Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials. 14
Phase I clinical study with 8-Chloro-cAMP and evaluation of immunological effects in cancer patients. 14
Inhibitors of HER/erB receptors: biological bases and clinical applications 14
Growth inhibition of human colon carcinoma cells by combinations of anti-EGF-related growth factor antisense oligonucleotides 14
Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays? 12
Effects of mutant p53 genes on transformation of human mammary epithelial cells. 12
Down-regulation of type I protein kinase A by transfection of human breast cancer cells with an epidermal growth factor receptor antisense expression vector. 11
Totale 3.003
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11.871
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.871
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20197 0 0 0 0 0 0 0 0 0 0 0 7
2019/2020473 116 2 70 1 72 7 1 0 0 32 50 122
2020/2021612 2 71 78 76 75 83 75 1 71 7 70 3
2021/2022516 12 2 2 8 9 9 8 18 68 30 138 212
2022/2023671 96 81 22 40 74 76 6 49 93 86 37 11
2023/2024324 19 67 37 68 19 24 16 58 10 6 0 0
Totale 3.073